The usefulness of carcinoembryonic antigen testing in the overall management of patients with non-small-cell lung cancer.
Carcinoembryonic antigen (CEA) testing is a valuable adjunct in the overall management of patients who have non-small-cell lung cancer, especially when selecting surgical candidates for curative lung resection and in cases where the diagnosis is in doubt. Carcinoembryonic antigen levels above 50 strongly suggest advanced-stage cancer and should discourage lung resections in otherwise suitable cases. Carcinoembryonic antigen testing can enhance problem solving in difficult cases and help prevent needless invasive interventions.
Sadoff
L
L
Department of Hematology and Oncology, Kaiser Permanente Medical Center, Los Angeles, California, USA.
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002272:Carcinoembryonic Antigen / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000175:diagnosis* / Q000628:therapy; D003937:Diagnosis, Differential; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000628:therapy; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000175:diagnosis*; D009367:Neoplasm Staging
D000970:Antineoplastic Agents; D002272:Carcinoembryonic Antigen